Fluidigm Announces Agenda for 9th Annual Mass Cytometry Summit
September 15 2020 - 8:30AM
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced the agenda for the 9th Annual
Fluidigm Mass Cytometry Summit on September 23. The full-day,
virtual event showcases CyTOF® technology and its use in
high-parameter suspension mass cytometry and Imaging Mass
Cytometry™.
Each year, the Mass Cytometry Summit underscores the significant
role that mass cytometry plays in immunology, immune function,
immuno-oncology and infectious disease, including discovery of
important new biomarkers. Presentations by leading translational
and clinical researchers from major academic institutions and
pharmaceutical companies detail work using CyTOF technology to
uncover new insights across a range of diseases. The 2020 Summit
emphasizes the latest CyTOF based discoveries in infectious
disease, immunology and the tumor microenvironment.
“The annual Summit provides a unique forum for customers who are
making meaningful contributions across all of life science, solving
some of the most complex challenges in translational and clinical
research,” said Chris Linthwaite, President and CEO. “Researchers
using the powerful capabilities of our CyTOF technology are at the
forefront of discovery of new biomarkers for disease insight and
treatment, evidenced by its use in more than 100 clinical research
trials and over 1,000 peer-reviewed publications. Increasingly,
this technology is proving critical in exploring immune response to
infection and in vaccine development as researchers grapple with
the COVID-19 global health crisis.”
The 2020 Summit will include presentations detailing new and
unique applications for CyTOF systems that enhance and simplify
large, multi-site translational and clinical research studies in
immunology and infectious disease. These include live-cell
barcoding for sample multiplexing, which enables larger studies and
reduces sample-to-sample variability; infectious disease-tailored
expansion panels for the company’s popular Maxpar® Direct™ Immune
Profiling Assay™; and the improved Maxpar Panel Designer v2.0. The
event will also highlight Fluidigm® Therapeutic Insights Services,
designed to provide broader researcher access to mass cytometry and
Imaging Mass Cytometry (IMC™).
Notable presenters include:
- Rebecca Ihrie, PhD, Associate Professor of Cell and
Developmental Biology, Vanderbilt University (Keynote)
- Marcelo Sztein, MD, Professor of Pediatrics, Associate Director
for Basic and Translational Research, Immunology Group Leader,
Center for Vaccine Development and Global Health, University of
Maryland (Keynote)
- Bernd Bodenmiller, PhD, Professor for Quantitative Biology,
Department of Quantitative Biomedicine, University of Zurich
- Jared K. Burks, PhD, Associate Professor, Co-Director, Flow
Cytometry and Cellular Imaging Core Facility, University of Texas
MD Anderson Cancer Center
- Kara L. Davis, DO, Assistant Professor of Pediatrics, Maternal
& Child Health Research Institute, Stanford University
- Melissa Davis, PhD, Assistant Professor of Cell and
Developmental Biology, Weill Cornell Medical College
- Raphael Gottardo, PhD, J. Orin Edson Foundation Endowed Chair,
Scientific Director, Translational Data Science Integrated Research
Center, Fred Hutchinson Cancer Research Center
- Won Jin Ho, MD, Assistant Professor of Oncology, Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins
- Philip Hobson, PhD, Deputy Head of Flow Cytometry, The Francis
Crick Institute
- Amir Horowitz, PhD, Assistant Professor of Oncological
Sciences, Precision Immunology Institute/Tisch Cancer Institute,
Icahn School of Medicine at Mount Sinai
- Akil Merchant, MD, Associate Professor and Director of Imaging
Mass Cytometry Shared Resource, Cedars-Sinai Medical Center
- Handan Xiang, PhD, Senior Scientist, Merck Research
Laboratories
Registration The Annual Mass Cytometry Summit
is an international meeting of the mass cytometry community
designed for both new and experienced users, as well as those
simply interested in learning more about CyTOF technology and its
use in high-parameter cytometry (suspension mass cytometry) and
IMC. In addition to major presentations, there will be plenary
sessions covering multiple applications, special-topic
breakout sessions and tutorials. Register here.
About FluidigmFluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF® and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, and plant and animal research
laboratories worldwide. Together with them, we strive to increase
the quality of life for all. For more information,
visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Direct, Imaging
Mass Cytometry, IMC, Immune Profiling Assay, and Maxpar are
trademarks and/or registered trademarks of Fluidigm
Corporation in the United States and/or other
countries. All other trademarks are the sole property of their
respective owners. Fluidigm products are provided for Research
Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements for FluidigmThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding research applications
for mass cytometry and the potential benefits of Fluidigm products
for such research. Forward-looking statements are subject to
numerous risks and uncertainties that could cause actual results to
differ materially from currently anticipated results, including but
not limited to risks relating to challenges inherent in developing,
manufacturing, launching, marketing, and selling new products;
potential product performance and quality issues; intellectual
property risks; and competition. Information on these and
additional risks and uncertainties and other information affecting
Fluidigm business and operating results is contained in Fluidigm’s
Annual Report on Form 10-K for the year ended December 31, 2019,
and in its other filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof. Fluidigm disclaims any obligation to update these
forward-looking statements except as may be required by law.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and webcasts.
Fluidigm
Media: Mark Spearman Senior Director, Corporate
Communications 650 243 6621mark.spearman@fluidigm.com
Investors: Agnes Lee Vice President, Investor
Relations 650 416 7423agnes.lee@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Sep 2023 to Sep 2024